Tomoyuki Tahara

8486402, Jul 16, 2013

May 12, 2011

13/106280

Tomoyuki Tahara - San Diego CA, US
Yoshikatsu Kanai - Tokyo-to, JP
Hitoshi Endou - Tokyo-to, JP
Shiro Kataoka - Tokyo-to, JP
Kazumasa Hasegawa - Gunma-ken, JP
Tetsuya Yoshino - Gunma-ken, JP

Kyowa Hakko Kirin Co., Ltd - Tokyo

A61K 38/00

4241421, 4241341, 4241781, 4241811, 53038815, 5303913, 5303917

A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.

8623370, Jan 7, 2014

Oct 6, 2008

12/682539

Shinichiro Kato - Chiba, JP
Steve Granger - Encinitas CA, US
Shane Crotty - San Diego CA, US
Sandra Rickert - Encinitas CA, US
Lilia Koriazova - San Diego CA, US
Tomoyuki Tahara - San Diego CA, US

Kyowa Hakko Kirin Co., Ltd. - Tokyo
La Jolla Institute for Allergy and Immunology - La Jolla CA

A61K 39/395
A61K 39/42

4241591, 4241301, 4241411, 4241471

The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to pox virus H3L envelope protein, and combinations thereof.

20100143367, Jun 10, 2010

Apr 5, 2007

12/295991

Tomoyuki Tahara - San Diego CA, US
Yoshikatsu Kanai - Tokyo-to, JP
Hitoshi Endou - Tokyo-to, JP
Shiro Kataoka - Tokyo-to, JP
Kazumasa Hasegawa - Gunma-ken, JP
Tetsuya Yoshino - Gunma-ken, JP

A61K 39/395
C07K 16/00
C07H 21/00
C12P 21/08
A61P 35/00
C12N 15/63
C12N 5/10

4241421, 53038815, 5303913, 5303917, 536 231, 4353201, 435325, 435 696

A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.

20140212409, Jul 31, 2014

Aug 13, 2013

13/965347

- Tokyo, JP
Mami KOYAMA - La Jolla CA, US
Yutaka KANDA - La Jolla CA, US
Tomoyuki TAHARA - La Jolla CA, US

KYOWA HAKKO KIRIN CO., LTD. - Tokyo

C07K 16/12

4241331

The present invention relates to a method for increasing deposition of complement C3b on the bacterial surface and phagocytosis by phagocytes, a therapeutic method and a therapeutic agent for bacterial infections, using an antibody binding to a molecule on the bacterial surface, in which the antibody is modified by substituting at least one amino acid residue with other amino acid so as to show more enhanced complement-dependent cytotoxicity (CDC) than the antibody before substitution of the amino acid residue.

20140186370, Jul 3, 2014

Dec 27, 2013

14/142520

- Tokyo, JP
- La Jolla CA, US
SHANE CROTTY - San Diego CA, US
SANDRA RICKERT - Encinitas CA, US
LILIA KORIAZOVA - San Diego CA, US
TOMOYUKI TAHARA - San Diego CA, US

LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY - La Jolla CA
KYOWA HAKKO KIRIN CO., LTD. - Tokyo

C07K 16/08

4241591, 5303894

The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to poxvirus H3L envelope protein, and combinations thereof.